Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Clinical Guidelines |6 March 2018

Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline Free

Robert M. Carey, MD; Paul K. Whelton, MB, MD, MSc; for the 2017 ACC/AHA Hypertension Guideline Writing Committee *

Robert M. Carey, MD
University of Virginia Health System, Charlottesville, Virginia (R.M.C.)

Paul K. Whelton, MB, MD, MSc
Tulane University School of Public Health and Tropical Medicine and Tulane School of Medicine, New Orleans, Louisiana (P.K.W.)

for the 2017 ACC/AHA Hypertension Guideline Writing Committee

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 23 January 2018.
* For a list of the members of the 2017 ACC/AHA Hypertension Guideline Writing Committee, see the  Appendix.
  • University of Virginia Health System, Charlottesville, Virginia (R.M.C.)
    Tulane University School of Public Health and Tropical Medicine and Tulane School of Medicine, New Orleans, Louisiana (P.K.W.)

    Acknowledgment: The authors thank the members of the writing committee (see Appendix); the ACC and the AHA; Katherine Sheehan, PhD, ACC/AHA Director of Guideline Strategy and Operations; Naira Tahir, MPH, Associate Guideline Advisor; Abdul Abdulla, MD, Science and Medicine Advisor; Glenn N. Levine, MD, ACC/AHA Task Force Chair; and the following partnering professional organizations: American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Geriatrics Society, American Pharmacists Association, American Society of Hypertension, American Society for Preventive Cardiology, National Medical Association, and Preventive Cardiovascular Nurses Association.

    Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-3203.

    Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.

    Requests for Single Reprints: Robert M. Carey, MD, University of Virginia Health System, PO Box 801414, Charlottesville, VA 22908-1414.

    Current Author Addresses: Dr. Carey: University of Virginia Health System, PO Box 801414, Charlottesville, VA 22908-1414.

    Dr. Whelton: Tulane University School of Public Health and Tropical Medicine and Tulane School of Medicine, 1440 Canal Street, New Orleans, LA 70112.

    Author Contributions: Conception and design: R.M. Carey, P.K. Whelton.

    Analysis and interpretation of the data: R.M. Carey, P.K. Whelton.

    Drafting of the article: R.M. Carey.

    Critical revision of the article for important intellectual content: R.M. Carey, P.K. Whelton.

    Final approval of the article: R.M. Carey, P.K. Whelton.

    Administrative, technical, or logistic support: P.K. Whelton.

    Collection and assembly of data: P.K. Whelton.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Guideline Development Process
    • Recommendations
    • Appendix: 2017 ACC/AHA Hypertension Guideline Writing Committee
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

Abstract

Description:

In November 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a clinical practice guideline for the prevention, detection, evaluation, and treatment of high blood pressure (BP) in adults. This article summarizes the major recommendations.

Methods:

In 2014, the ACC and the AHA appointed a multidisciplinary committee to update previous reports of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The committee reviewed literature and commissioned systematic reviews and meta-analyses on out-of-office BP monitoring, the optimal target for BP lowering, the comparative benefits and harms of different classes of antihypertensive agents, and the comparative benefits and harms of initiating therapy with a single antihypertensive agent or a combination of 2 agents.

Recommendations:

This article summarizes key recommendations in the following areas: BP classification, BP measurement, screening for secondary hypertension, nonpharmacologic therapy, BP thresholds and cardiac risk estimation to guide drug treatment, treatment goals (general and for patients with diabetes mellitus, chronic kidney disease, and advanced age), choice of initial drug therapy, resistant hypertension, and strategies to improve hypertension control.

Hypertension is the leading cause of death and disability-adjusted life-years worldwide (1, 2). In the United States, hypertension accounts for more cardiovascular disease (CVD) deaths than any other modifiable risk factor and is second only to cigarette smoking as a preventable cause of death for any reason (3). The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults provides an evidence-based approach to reduction of CVD risk through lowering of blood pressure (BP) (4).

Guideline Development Process

In 1977, the National Heart, Lung, and Blood Institute (NHLBI) initiated a series of hypertension guidelines, culminating in the 2003 publication of The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (5). In 2013, the NHLBI transferred responsibility for sponsorship of clinical practice guidelines for CVD prevention to the ACC and the AHA (6). In 2014, the ACC and the AHA partnered with 9 other professional associations to develop a new hypertension clinical practice guideline. A 21-member panel of multidisciplinary experts (physicians, nurses, pharmacists, and patient representatives) with no BP-related industry relationships developed the 2017 guideline.
The writing committee conducted a structured review of the literature and commissioned 4 systematic reviews (and meta-analyses when feasible) from an independent evidence review committee to address the following: 1) self-directed and/or ambulatory BP monitoring compared with office-based BP measurement to prevent adverse outcomes and achieve better BP control, 2) the optimal target for BP lowering during antihypertensive therapy, 3) whether various antihypertensive drug classes differ in their comparative benefits and/or harms as first-line treatment, and 4) whether initiating treatment with 1 antihypertensive drug (monotherapy) is more or less beneficial than starting with 2 drugs (7).
The writing committee used the methods of the ACC/AHA Task Force on Clinical Practice Guidelines (8) to make 106 recommendations, each characterized by class (strength) of recommendation (an estimate of the magnitude and certainty of benefit in proportion to risk) and level (quality) of evidence (rating the type, quantity, and consistency of data from clinical trials and other sources). Five “official” reviewers from the ACC and the AHA, 9 “organizational” reviewers representing the partner professional organizations, and 38 “content” reviewers with expertise in hypertension reviewed the recommendations before approval by the governing bodies of the ACC, the AHA, the American Society for Preventive Cardiology, the Preventive Cardiovascular Nurses Association, the American Academy of Physician Assistants, the Association of Black Cardiologists, the American Pharmacists Association, the American College of Preventive Medicine, the American Society of Hypertension, the American Geriatrics Society, and the National Medical Association. A complete description of the methods, the evidence reviews, and the recommendations is available at www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults. This synopsis summarizes major recommendations for generalist clinicians.

Recommendations

Classification of BP and Diagnosis of Hypertension

Table 1 shows BP classifications. Although the definition of normal BP remains the same as in JNC 7 (average systolic BP [SBP] <120 mm Hg and average diastolic BP [DBP] <80 mm Hg), the 2017 guideline replaces the term “prehypertension” with “elevated BP” (average SBP of 120 to 129 mm Hg and average DBP <80 mm Hg) and “stage 1 hypertension” (average SBP of 130 to 139 mm Hg or average DBP of 80 to 89 mm Hg). Stage 2 hypertension is defined as an average SBP of at least 140 mm Hg or an average DBP of at least 90 mm Hg instead of a BP of at least 160/100 mm Hg. The upper end of prehypertension was reclassified as stage 1 hypertension because adults with BP in this range have an approximately 2-fold increase in CVD risk compared with adults with normal BP, and recent randomized clinical trials have demonstrated benefit with an SBP below 130 mm Hg (9–13). This change in BP classification is estimated to result in an increase of about 14% in the prevalence of hypertension in the United States but only a 1.9% increase in adults requiring antihypertensive drug therapy (14).

Table 1. Classification of BP*

Table 1. Classification of BP*

Measurement of BP

Proper methods of BP measurement, which are detailed in the guideline (4), are fundamental to categorizing BP, ascertaining BP-related CVD risk, and managing hypertension. The guideline urges clinicians to obtain accurate measurements and base their estimates of BP on an average of at least 2 readings obtained on at least 2 separate occasions (Table 2).

Table 2. Recommendations for Measurement of BP*

Table 2. Recommendations for Measurement of BP*
The guideline recommends greater use of out-of-office BP measurements to confirm the diagnosis of hypertension and titrate medication. In adults who are not using antihypertensive drugs, ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) should be used to detect white coat hypertension (high office BP but normal out-of-office BP) and masked hypertension (normal office BP but high out-of-office BP) (Figure 1). White coat hypertension is associated with a CVD risk approximating that of normal BP, whereas masked hypertension carries a CVD risk similar to that of sustained hypertension. In adults already using antihypertensive drugs, the guideline recommends screening for masked uncontrolled hypertension if the office BP is at goal but CVD risk is increased or target organ damage is present. If the office BP is more than 5 to 10 mm Hg above goal in a patient using 3 or more antihypertensive drugs, the guideline recommends HBPM to detect a white coat effect (Figure 2).
Figure 1.

Algorithm for detection of white coat hypertension or masked hypertension in patients not receiving antihypertensive drug therapy.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring.

Figure 2.

Algorithm for detection of white coat effect or masked uncontrolled hypertension in patients receiving drug therapy.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CVD = cardiovascular disease; HBPM = home blood pressure monitoring.

Appendix Figure.

Applying class of recommendation and level of evidence to clinical strategies, interventions, treatments, or diagnostic testing in patient care*.

COR and LOE are determined independently (any COR may be paired with any LOE). A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) COR = class (strength) of recommendation; EO = expert opinion; LD = limited data; LOE = level (quality) of evidence; NR = nonrandomized; R = randomized; RCT = randomized controlled trial.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools and, for systematic reviews, the incorporation of an Evidence Review Committee.

Secondary Hypertension

A secondary cause of hypertension can be identified in approximately 10% of hypertensive adults, and specific treatment of the cause reduces CVD risk. Screening for a secondary cause is recommended in the circumstances listed in Table 3, with referral to a clinician with relevant expertise when screening results are positive.

Table 3. Screening for Secondary Hypertension*

Table 3. Screening for Secondary Hypertension*

Nonpharmacologic Interventions

Lifestyle changes alone are recommended for most adults newly classified as having stage 1 hypertension (130 to 139/80 to 89 mm Hg), and lifestyle changes plus drug therapy are recommended for those with existing CVD or increased CVD risk. Recommended lifestyle interventions are listed in Table 4.

Table 4. Recommendations for Nonpharmacologic and Pharmacologic Treatment and BP Goals*

Table 4. Recommendations for Nonpharmacologic and Pharmacologic Treatment and BP Goals*

BP Thresholds and Risk Estimation to Guide Pharmacologic Treatment

Figure 3 shows BP thresholds and recommendations for follow-up and treatment of normal BP, elevated BP, and stage 1 and 2 hypertension. Intensive BP-lowering therapies should be directed toward patients with the highest atherosclerotic cardiovascular disease (ASCVD) risk. Although drug treatment based on BP alone is cost-effective, basing treatment decisions on absolute ASCVD risk combined with BP is even more efficient and cost-effective in reducing CVD risk. Benefits of using a combination approach to guide drug treatment include focusing treatment on patients most likely to have CVD events and a larger absolute CVD risk reduction, preventing more CVD events, and saving more quality-adjusted life-years.
Figure 3.

BP thresholds and recommendations for treatment and follow-up.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CVD = cardiovascular disease.

* Using the American College of Cardiology/American Heart Association Pooled Cohort Equations. Patients with diabetes mellitus or chronic kidney disease are automatically placed in the high-risk category. For initiation of use of a renin–angiotensin system inhibitor or diuretic therapy, clinicians should assess blood tests for electrolytes and renal function 2 to 4 wk after initiating therapy.

† Clinicians should consider initiation of pharmacologic therapy for stage 2 hypertension with 2 antihypertensive agents from different classes. Patients with stage 2 hypertension and BP ≥160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control BP. Reassessment includes BP measurement, detection of orthostatic hypotension in selected patients (e.g., older patients or those with postural symptoms), identification of white coat hypertension or a white coat effect, documentation of adherence, monitoring of response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve the BP target.

For high-risk adults with stage 1 hypertension who have preexisting CVD or an estimated 10-year ASCVD risk of at least 10%, the guideline recommends initiating drug treatment for those with an average BP of 130/80 mm Hg or higher (class I recommendation, high-quality evidence). For lower-risk adults without preexisting CVD and an estimated 10-year ASCVD risk less than 10%, the BP threshold for drug treatment is 140/90 mm Hg or higher (class I recommendation, low-quality evidence) (Table 4).
The ACC/AHA Pooled Cohort Equations (http://tools.acc.org/ASCVD-Risk-Estimator), which are based on age, race, sex, cholesterol levels (total, low-density lipoprotein, and high-density lipoprotein), statin use, SBP, treatment for hypertension, history of diabetes mellitus (DM), current smoking, and aspirin use, are recommended to estimate 10-year risk for ASCVD, which is defined as a first nonfatal myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke among adults without CVD (15). Adults with DM, those with chronic kidney disease (CKD), and those aged 65 years or older are in the high–risk category for ASCVD.

BP Goals for Patients With Hypertension

Table 4 summarizes recommendations on BP thresholds and goals for treatment of adults with hypertension. After initiation of antihypertensive drug therapy, regardless of ASCVD risk, the recommended BP target is less than 130/80 mm Hg. The quality of evidence supporting this target is stronger for patients with known CVD or an estimated 10-year ASCVD risk of at least 10% than for patients without elevated risk. A recent systematic review and network meta-analysis showed continuing reduction in CVD risk (major cardiovascular events, stroke, coronary heart disease, and all-cause mortality) at progressively lower levels of achieved SBP (13). A sensitivity analysis demonstrated a similar pattern when the results of SPRINT (Systolic Blood Pressure Intervention Trial) were excluded (13).

Choice of Antihypertensive Drug Therapy

The evidence review conducted to inform the recommendations found some differences but general similarity in the efficacy and safety of drugs traditionally considered first-line agents, underscoring the importance of BP lowering above the choice of drug (7). Recommendations on initial agents are summarized in Table 4. For adults without a compelling indication for use of a specific drug, clinicians should initiate therapy with thiazide diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers. Thiazide diuretics (especially chlorthalidone) and calcium-channel blockers are the preferred options for first-line therapy in most U.S. adults because of their efficacy. In black patients, including those with DM, thiazide diuretics and calcium-channel blockers are recommended as first-line agents, whereas β-blockers and renin–angiotensin system inhibitors are less effective at lowering BP.
For patients with stage 2 hypertension, initiation of 2 antihypertensive agents from different classes is recommended when the average SBP and DBP are more than 20 and 10 mm Hg above target, respectively. Patients with stage 2 hypertension and an average BP of 160/100 mm Hg or higher should be treated promptly, should be carefully monitored, and should have prompt adjustment of their regimen until control is achieved.
After initiation of drug therapy, management should include monthly evaluation of adherence and therapeutic response until control is achieved. Interventions to promote control, such as HBPM, team-based care, and telehealth, are useful in improving BP control.

BP Thresholds and Goals in Adults With DM

Although the guideline encourages ASCVD risk assessment in all adults with hypertension, including those with DM, clinicians can assume for the sake of convenience that most adults with DM and hypertension have a 10-year ASCVD risk of at least 10%, placing them in a high-risk category that requires initiation of drug therapy at a BP of 130/80 mm Hg or higher. Although the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial did not document a statistically significant reduction in the primary outcome (CVD composite) with intensive versus standard BP lowering, the trial was underpowered to detect a difference between treatment groups, and interpretation of the results was complicated by use of a factorial design (16). SPRINT demonstrated a CVD benefit from intensive treatment to an SBP goal of less than 120 mm Hg but did not include patients with DM (17). Meta-analysis of the SPRINT and ACCORD results suggested that the findings of both trials were consistent (18). A post hoc analysis of SPRINT suggested that patients with prediabetes derived similar benefit compared with normoglycemic patients (19). Thus, the guideline recommends that antihypertensive drug treatment should be initiated at a BP of 130/80 mm Hg or higher in adults with DM, and the treatment goal should be less than 130/80 mm Hg (Table 4).

BP Thresholds and Goals in Adults With CKD

Hypertension has been reported in 67% to 92% of patients with CKD, with increasing prevalence as renal function declines. High BP may occur as a consequence of kidney disease, but even in this context, its presence is likely to lead to an acceleration in further kidney injury. Similar to patients with DM, those with CKD and hypertension are automatically assigned to the high–risk category for ASCVD, with the BP threshold for pharmacologic treatment at 130/80 mm Hg or higher. Given that most patients with CKD die of CVD complications, evidence from SPRINT supports a BP target of less than 130/80 mm Hg for patients with CKD (Table 4) (17).

BP Thresholds and Goals in Older Adults

Hypertension is a leading cause of preventable morbidity and mortality in older adults and is a major contributor to their premature disability and institutionalization. Isolated systolic hypertension is the predominant form of hypertension in older persons. Randomized trials of antihypertensive therapy have included large numbers of older adults, and in every instance, including when the SBP treatment goal was less than 120 mm Hg, more intensive BP-lowering therapy safely reduced risk for CVD events for those older than 65, 75, and 80 years. Both HYVET (Hypertension in the Very Elderly Trial) and SPRINT included older persons who were frail but still living independently in the community, and both found substantial benefit in those who received more intensive BP treatment (17, 20). Blood pressure–lowering therapy is one of a few interventions that has been shown to reduce risk for death in frail older adults. Initiation of BP-lowering therapy, especially with 2 drugs, should be done with caution in older persons, and careful monitoring for adverse effects, including orthostatic hypotension, is essential.
Although the guideline encourages ASCVD risk assessment in all adults with hypertension, including older persons, clinicians can assume for the sake of convenience that adults aged 65 years or older with hypertension have a 10-year ASCVD risk of at least 10%, placing them in a high-risk category that requires initiation of drug therapy at an SBP of 130 mm Hg or higher. Treatment of hypertension with an SBP goal of less than 130 mm Hg is recommended for noninstitutionalized, ambulatory, community-dwelling adults aged 65 years or older with an average SBP of 130 mm Hg or higher (Table 4). Careful titration of BP-lowering medications and close monitoring are especially important in older adults with a high burden of comorbidity because large trials have excluded many such persons. For older adults (aged ≥65 years) with hypertension, a high burden of comorbidity, and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess the risk–benefit tradeoffs of treatment are reasonable for decisions about the choice of drug and intensity of BP control (Table 4).

Management of Resistant Hypertension

Resistant hypertension is defined as an average office BP of 130/80 mm Hg or higher in patients adhering to 3 or more antihypertensive agents from different classes at optimal doses, including a diuretic, or in those requiring 4 or more antihypertensive medications. Using the former BP target of less than 140/90 mm Hg, the prevalence of resistant hypertension has been estimated to be 13% among hypertensive adults. Estimates suggest that the prevalence of resistant hypertension will be about 4% higher with the new BP target of less than 130/80 mm Hg (4). Risk for myocardial infarction, stroke, end-stage renal disease, and death in adults with resistant hypertension (using the previous definition) is 2- to 6-fold higher than in adults with hypertension that is not resistant to treatment. Clinicians caring for patients who fulfill the criteria for resistant hypertension should ensure that the diagnosis is based on accurate office BP measurements, assess for nonadherence to the prescribed antihypertensive medications, and obtain home or ambulatory BP readings to rule out the white coat effect. Contributing lifestyle factors should be identified and addressed. Use of substances that interfere with antihypertensive therapy, such as nonsteroidal anti-inflammatory drugs, stimulants, and oral contraceptives, should be discontinued or minimized, and secondary causes of hypertension should be excluded.
Treatment of resistant hypertension includes maximization of diuretic therapy (chlorthalidone or indapamide instead of hydrochlorothiazide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), addition of other agents with different mechanisms of action, use of loop diuretics in patients with CKD, and referral to a hypertension specialist if BP remains uncontrolled (Table 5).

Table 5. Recommendations for Managing Resistant Hypertension and Improving Hypertension Management*

Table 5. Recommendations for Managing Resistant Hypertension and Improving Hypertension Management*

Strategies to Improve Hypertension Treatment and Control

Every adult with hypertension should have an evidence-based care plan that promotes treatment and self-management goals, effective management of comorbid conditions, timely follow-up, and CVD guideline–directed management (Table 5). Up to 25% of patients do not fill their initial prescription for antihypertensive drug therapy, and only 1 in 5 patients has sufficiently high adherence to achieve the benefits observed in randomized controlled trials (21). Once-daily dosing of antihypertensive medication and use of combination pills can improve adherence.
A team-based care approach is recommended for adults with hypertension. In addition, use of the electronic health record and patient registries is beneficial in recognizing uncontrolled hypertension and guiding initiatives for quality improvement in hypertension control. Telehealth strategies also can be useful adjuncts to interventions shown to lower BP for adults with hypertension.

Summary

Hypertension is a leading risk factor for death and disability-adjusted life-years worldwide. Blood pressure of 120/80 mm Hg or higher is linearly related to risk for fatal and nonfatal stroke, ischemic heart disease, and noncardiac vascular disease, and each increase of 20/10 mm Hg doubles the risk for a fatal CVD event. The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (4) is the first comprehensive hypertension clinical practice guideline since 2003. The 2017 guideline uses a different classification system for BP than previous guidelines; emphasizes out-of-office BP measurements to confirm the diagnosis of and monitor success in control of hypertension; advocates team-based care and use of the electronic health record and telehealth strategies for improved care; recommends nonpharmacologic interventions; and recommends addition of antihypertensive drug therapy based on a combination of average BP, ASCVD risk, and comorbid conditions.

Appendix: 2017 ACC/AHA Hypertension Guideline Writing Committee

Paul K. Whelton, MB, MD, MPH, Chair*
Robert M. Carey, MD, Vice Chair*
Wilbert S. Aronow, MD†
Donald E. Casey, MD, MPH, MBA†
Karen J. Collins, MBA†
Cheryl Dennison Himmelfarb, RN, PhD†
Sondra M. DePalma, MHS†
Sammuel Gidding, MD†
Kenneth A. Jamerson, MD†
Daniel W. Jones, MD†
Eric J. McLaughlin, PharmD†
Paul Muntner, PhD†
Bruce Ovbiagele, MD, MSc, MAS†
Sidney C. Smith Jr., MD†
Crystal C. Spencer, JD†
Randall S. Stafford, MD, PhD†
Sandra J. Taler, MD†
Randall J. Thomas, MD, MS†
Kim A. Williams Sr., MD†
Jeff D. Williamson, MD, MHS†
Jackson T. Wright, MD, PhD†
* Author.
† Nonauthor contributor.

References

  1. Lim
    SS
    ,  
    Vos
    T
    ,  
    Flaxman
    AD
    ,  
    Danaei
    G
    ,  
    Shibuya
    K
    ,  
    Adair-Rohani
    H
    ,  
    et al
    A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.
    Lancet
    2012
    380
    2224
    60
     PubMed
    CrossRef
     PubMed
  2. Forouzanfar
    MH
    ,  
    Liu
    P
    ,  
    Roth
    GA
    ,  
    Ng
    M
    ,  
    Biryukov
    S
    ,  
    Marczak
    L
    ,  
    et al
    Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015.
    JAMA
    2017
    317
    165
    82
     PubMed
    CrossRef
     PubMed
  3. Danaei
    G
    ,  
    Ding
    EL
    ,  
    Mozaffarian
    D
    ,  
    Taylor
    B
    ,  
    Rehm
    J
    ,  
    Murray
    CJ
    ,  
    et al
    The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors.
    PLoS Med
    2009
    6
    e1000058
     PubMed
    CrossRef
     PubMed
  4. Whelton
    PK
    ,  
    Carey
    RM
    ,  
    Aronow
    WS
    ,  
    Casey
    DE
    Jr
    ,  
    Collins
    KJ
    ,  
    Dennison Himmelfarb
    C
    ,  
    et al
    2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Hypertension
    2017
     PubMed
  5. Chobanian
    AV
    ,  
    Bakris
    GL
    ,  
    Black
    HR
    ,  
    Cushman
    WC
    ,  
    Green
    LA
    ,  
    Izzo
    JL
    Jr
    ,  
    et al
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    National Heart, Lung, and Blood Institute. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
    Hypertension
    2003
    42
    1206
    52
     PubMed
    CrossRef
     PubMed
  6. Gibbons
    GH
    ,  
    Harold
    JG
    ,  
    Jessup
    M
    ,  
    Robertson
    RM
    ,  
    Oetgen
    WJ
    .  
    The next steps in developing clinical practice guidelines for prevention.
    Circulation
    2013
    128
    1716
    7
     PubMed
    CrossRef
     PubMed
  7. Reboussin
    DM
    ,  
    Allen
    NB
    ,  
    Griswold
    ME
    ,  
    Guallar
    E
    ,  
    Hong
    Y
    ,  
    Lackland
    DT
    ,  
    et al
    Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Hypertension
    2017
     PubMed
  8. Jacobs
    AK
    ,  
    Anderson
    JL
    ,  
    Halperin
    JL
    ,  
    Anderson
    JL
    ,  
    Halperin
    JL
    ,  
    Albert
    NM
    ,  
    et al
    ACC/AHA Task Force Members
    The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Circulation
    2014
    130
    1208
    17
     PubMed
    CrossRef
     PubMed
  9. Thomopolous
    C
    ,  
    Parati
    G
    ,  
    Zanchetti
    A
    .  
    Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs less intensive blood pressure lowering and different achieved blood pressure levels—updated overview and meta-analysis of randomized trials.
    J Hypertens
    2016
    34
    613
    22
    CrossRef
     PubMed
  10. Xie
    X
    ,  
    Atkins
    E
    ,  
    Lv
    J
    ,  
    Bennett
    A
    ,  
    Neal
    B
    ,  
    Ninomiya
    T
    ,  
    et al
    Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
    Lancet
    2016
    387
    435
    43
     PubMed
    CrossRef
     PubMed
  11. Verdecchia
    P
    ,  
    Angeli
    F
    ,  
    Gentile
    G
    ,  
    Reboldi
    G
    .  
    More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis.
    Hypertension
    2016
    68
    642
    53
     PubMed
    CrossRef
     PubMed
  12. Bangalore
    S
    ,  
    Toklu
    B
    ,  
    Gianos
    E
    ,  
    Schwartzbard
    A
    ,  
    Weintraub
    H
    ,  
    Ogedegbe
    G
    ,  
    et al
    Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials.
    Am J Med
    2017
    130
    707
    19
     PubMed
    CrossRef
     PubMed
  13. Bundy
    JD
    ,  
    Li
    C
    ,  
    Stuchlik
    P
    ,  
    Bu
    X
    ,  
    Kelly
    TN
    ,  
    Mills
    KT
    ,  
    et al
    Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis.
    JAMA Cardiol
    2017
    2
    775
    81
     PubMed
    CrossRef
     PubMed
  14. Muntner
    P
    ,  
    Carey
    RM
    ,  
    Gidding
    S
    ,  
    Jones
    DW
    ,  
    Taler
    SJ
    ,  
    Wright
    JT
    Jr
    ,  
    et al
    Potential U.S.
    population impact of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline
    Circulation. 2017
     PubMed
  15. Goff
    DC
    Jr
    ,  
    Lloyd-Jones
    DM
    ,  
    Bennett
    G
    ,  
    Coady
    S
    ,  
    D'Agostino
    RB
    ,  
    Gibbons
    R
    ,  
    et al
    American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Circulation
    2014
    129
    S49
    73
     PubMed
    CrossRef
     PubMed
  16. Cushman
    WC
    ,  
    Evans
    GW
    ,  
    Byington
    RP
    ,  
    Goff
    DC
    Jr
    ,  
    Grimm
    RH
    Jr
    ,  
    Cutler
    JA
    ,  
    et al
    ACCORD Study Group
    Effects of intensive blood-pressure control in type 2 diabetes mellitus.
    N Engl J Med
    2010
    362
    1575
    85
     PubMed
    CrossRef
     PubMed
  17. Wright
    JT
    Jr
    ,  
    Williamson
    JD
    ,  
    Whelton
    PK
    ,  
    Snyder
    JK
    ,  
    Sink
    KM
    ,  
    Rocco
    MV
    ,  
    et al
    SPRINT Research Group
    A randomized trial of intensive versus standard blood-pressure control.
    N Engl J Med
    2015
    373
    2103
    16
     PubMed
    CrossRef
     PubMed
  18. Perkovic
    V
    ,  
    Rodgers
    A
    .  
    Redefining blood-pressure targets—SPRINT starts the marathon [Editorial].
    N Engl J Med
    2015
    373
    2175
    8
     PubMed
    CrossRef
     PubMed
  19. Bress
    AP
    ,  
    King
    JB
    ,  
    Kreider
    KE
    ,  
    Beddhu
    S
    ,  
    Simmons
    DL
    ,  
    Cheung
    AK
    ,  
    et al
    SPRINT Research Group
    Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial.
    Diabetes Care
    2017
     PubMed
  20. Warwick
    J
    ,  
    Falaschetti
    E
    ,  
    Rockwood
    K
    ,  
    Mitnitski
    A
    ,  
    Thijs
    L
    ,  
    Beckett
    N
    ,  
    et al
    No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over.
    BMC Med
    2015
    13
    78
     PubMed
    CrossRef
     PubMed
  21. Berra
    E
    ,  
    Azizi
    M
    ,  
    Capron
    A
    ,  
    Høieggen
    A
    ,  
    Rabbia
    F
    ,  
    Kjeldsen
    SE
    ,  
    et al
    Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension.
    Hypertension
    2016
    68
    297
    306
     PubMed
    CrossRef
     PubMed
Figure 1.

Algorithm for detection of white coat hypertension or masked hypertension in patients not receiving antihypertensive drug therapy.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring.

Figure 2.

Algorithm for detection of white coat effect or masked uncontrolled hypertension in patients receiving drug therapy.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CVD = cardiovascular disease; HBPM = home blood pressure monitoring.

Appendix Figure.

Applying class of recommendation and level of evidence to clinical strategies, interventions, treatments, or diagnostic testing in patient care*.

COR and LOE are determined independently (any COR may be paired with any LOE). A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) COR = class (strength) of recommendation; EO = expert opinion; LD = limited data; LOE = level (quality) of evidence; NR = nonrandomized; R = randomized; RCT = randomized controlled trial.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools and, for systematic reviews, the incorporation of an Evidence Review Committee.

Figure 3.

BP thresholds and recommendations for treatment and follow-up.

Colors correspond to class of recommendation in the Appendix Figure. (Reproduced with permission of the American College of Cardiology and the American Heart Association.) ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CVD = cardiovascular disease.

* Using the American College of Cardiology/American Heart Association Pooled Cohort Equations. Patients with diabetes mellitus or chronic kidney disease are automatically placed in the high-risk category. For initiation of use of a renin–angiotensin system inhibitor or diuretic therapy, clinicians should assess blood tests for electrolytes and renal function 2 to 4 wk after initiating therapy.

† Clinicians should consider initiation of pharmacologic therapy for stage 2 hypertension with 2 antihypertensive agents from different classes. Patients with stage 2 hypertension and BP ≥160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control BP. Reassessment includes BP measurement, detection of orthostatic hypotension in selected patients (e.g., older patients or those with postural symptoms), identification of white coat hypertension or a white coat effect, documentation of adherence, monitoring of response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve the BP target.

Table 1. Classification of BP*

Table 1. Classification of BP*

Table 2. Recommendations for Measurement of BP*

Table 2. Recommendations for Measurement of BP*

Table 3. Screening for Secondary Hypertension*

Table 3. Screening for Secondary Hypertension*

Table 4. Recommendations for Nonpharmacologic and Pharmacologic Treatment and BP Goals*

Table 4. Recommendations for Nonpharmacologic and Pharmacologic Treatment and BP Goals*

Table 5. Recommendations for Managing Resistant Hypertension and Improving Hypertension Management*

Table 5. Recommendations for Managing Resistant Hypertension and Improving Hypertension Management*

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Carey RM, Whelton PK, for the 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168:351–358. [Epub ahead of print 23 January 2018]. doi: https://doi.org/10.7326/M17-3203

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2018;168(5):351-358.

DOI: 10.7326/M17-3203

Published at www.annals.org on 23 January 2018

©
2018 American College of Physicians
37 Citations

See Also

The 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Resource for Practicing Clinicians
Hypertension Limbo: Balancing Benefits, Harms, and Patient Preferences Before We Lower the Bar on Blood Pressure
Annals On Call - Hypertension Limbo
View MoreView Less

Related Articles

The Response of Metabolic Alkalosis in Severe Hypertension to Antihypertensive Drugs
Annals of Internal Medicine; 58 (2): 336-340
The 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Resource for Practicing Clinicians
Annals of Internal Medicine; 168 (5): 359-360
Annals for Educators - 6 March 2018
Annals of Internal Medicine; 168 (5): ED5
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines
Annals of Internal Medicine; 164 (10): 683-684
View MoreView Less

Journal Club

Review: In patients with mild hypertension and no CV disease, BP-lowering drugs reduce stroke and mortality
Annals of Internal Medicine; 162 (10): JC5
Pooled RCTs: BP-lowering drugs reduced major CV events; absolute reductions were greater with higher baseline risk
Annals of Internal Medicine; 161 (12): JC5
Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment
Annals of Internal Medicine; 161 (4): JC2
Review: Low-quality evidence fails to show that antihypertensive drugs affect outcomes in mild hypertension
Annals of Internal Medicine; 157 (12): JC6-6
View MoreView Less

Related Point of Care

Hypertension
Annals of Internal Medicine; 170 (9): ITC65-ITC80
Hypertension
Annals of Internal Medicine; 161 (11): ITC1
Hypertension
Annals of Internal Medicine; 149 (11): ITC6-1
Stable Ischemic Heart Disease
Annals of Internal Medicine; 171 (3): ITC17-ITC32
View MoreView Less

Related Topics

Cardiology
Coronary Risk Factors
Guidelines
Hypertension
Nephrology

Cardiology, Coronary Risk Factors, Guidelines, Hypertension, Nephrology.

PubMed Articles

Prevalence and Determinants of hypertension in India based on the 2017 ACC/AHA Guideline: Evidence from the India National Family Health Survey.
Am J Hypertens 2019.
Major adverse renal events (MARE): A proposal to unifying renal endpoints.
Nephrol Dial Transplant 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×